Compare MRKR & AIXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | AIXC |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 16.6M |
| IPO Year | 2010 | 2015 |
| Metric | MRKR | AIXC |
|---|---|---|
| Price | $1.21 | $1.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 79.6K | ★ 638.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.61 | ★ 53.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,983,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $936.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $0.59 |
| 52 Week High | $2.46 | $3.14 |
| Indicator | MRKR | AIXC |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 51.88 |
| Support Level | $1.07 | $0.64 |
| Resistance Level | $1.36 | $1.45 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 17.47 | 48.75 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
AIxCrypto Holdings Inc is a technology infrastructure company focused on the convergence of artificial intelligence and blockchain-based programmable systems. The Company develops software platforms and programmable infrastructure designed to facilitate the tokenization of real-world assets (RWA) and the deployment of Embodied Artificial Intelligence (EAI) in commercial environments. Its mission is to serve as the regulated, programmable infrastructure layer connecting traditional capital markets with on-chain systems and AI-enabled commercial systems.